Safety and efficacy of abciximab as an adjunct to percutaneous coronary intervention

References

• Centers for Disease Control and PreventionMorbidity and Mortality Weekly ReportJAMA200729713081309
   Google Scholar
• KungHsiang-ChingHoyertDonna LXuJiaquanMurphySherry LDeaths: Final Data for 2005National Vital Statistics Reports56104242008
   Google Scholar
• American Heart Association WebsiteHeart Disease and Stroke Statistics – 2008 Update37 URL: http://www.americanheart.org/downloadable/heart/1200082005246HS_Stats%202008.final.pdf.
   Google Scholar
• EPIC InvestigationUse of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplastyN Engl J Med19943309569618121459
   PubMed Web of Science ®Google Scholar
• EPILOG InvestigatorsPlatelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularizationN Engl J Med1997336168916969182212
   PubMed Web of Science ®Google Scholar
• EPISTENT InvestigatorsRandomised placebo-controlled and balloon-angioplasty controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. The EPISTENT investigators. Evaluation of platelet IIb/IIIa inhibitor for stentingLancet199835287929672272
   PubMed Web of Science ®Google Scholar
• TopolEJMoliternoDJHerrmannHCComparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularizationN Engl J Med20013441888189411419425
   PubMed Web of Science ®Google Scholar
• BatchelorWBTollesonTRHuangYRandomized comparison of platelet inhibition with abciximab, tirofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes: the COMPARE trial; comparison of measurements of platelet aggregation with aggrastat, reopro, and eptifibatideCirculation20021061470147612234950
   PubMed Web of Science ®Google Scholar
• KastratiAMehilliJNeumannFJAbciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trialJAMA20062951531153816533938
   PubMed Web of Science ®Google Scholar
• MehilliJKastratiASchuhlenHRandomized clinical trial of abciximab in diabetic patients undergoing elective percutaneous coronary interventions after treatment with a high loading dose of clopidogrelCirculation20041103627363515531766
   PubMed Web of Science ®Google Scholar
• KastratiAMehilliJNeumannFJAbciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment. The ISAR-REACT 2 Randomized TrialJAMA20062951531153816533938
   PubMed Web of Science ®Google Scholar
• LincoffAMBittlJAHarringtonRABivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trialJAMA200328985386312588269
   PubMed Web of Science ®Google Scholar
• Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE StudyLancet1997349142914359164316
   PubMed Web of Science ®Google Scholar
• GUSTO IV-ACS InvestigatorsEffect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trialLancet20013571915192411425411
   PubMed Web of Science ®Google Scholar
• JamesSArmstrongPCaliffRSafety and efficacy of abciximab combined with dalteparin in treatment of acute coronary syndromesEur Heart J2002231538154512242074
   PubMed Web of Science ®Google Scholar
• BertrandOFDe LarochelliereRRodes-CabauJA randomized study comparing same-day home discharge and abciximab bolus only to overnight hospitalization and abciximab bolus and infusion after transradial coronary stent implantationCirculation20061142636264317145988
   PubMed Web of Science ®Google Scholar
• ThieleHSchindlerKFriedenbergerJIntracoronary compared with intravenous bolus abciximab application in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: the randomized Leipzig immediate percutaneous coronary intervention abciximab IV versus IC in ST-elevation myocardial infarction trialCirculation2008118495718559698
   PubMed Web of Science ®Google Scholar
• StoneGWMcLaurinBTCoxDABivalirudin for patients with acute coronary syndromesN Engl J Med20063552203221617124018
   PubMed Web of Science ®Google Scholar
• StoneGWGrinesCLCoxDAA prospective, randomized trial comparing primary balloon angioplasty with or without abciximab to primary stenting with or without abciximab in acute myocardial infarction – primary endpoint analysis from the CADILLAC TrialN Engl J Med200234695796611919304
   PubMed Web of Science ®Google Scholar
• MontalescotGAntoniucciDKastratiAAbciximab in primary coronary stenting of ST-elevation myocardial infarction: a European meta-analysis on individual patients’ data with long-term follow-upEur Heart J20072844344917251257
   PubMed Web of Science ®Google Scholar
• EllisSGArmstrongPBetriuAFacilitated percutaneous coronary intervention versus primary percutaneous coronary intervention: design and rationale of the facilitated intervention with enhanced reperfusion speed to stop events (FINESSE) trialAm Heart J2004147E1615077099
   PubMed Web of Science ®Google Scholar
• StoneGWWitzenbichlerBGuagliumiGBivalirudin during primary PCI in acute myocardial infarctionN Engl J Med20083582218222318499566
   PubMed Web of Science ®Google Scholar
• ValgimigliMCampoGPercocoGon behalf of the Multicentre Evaluation of Single High-Dose Bolus Tirofiban vs Abciximab With Sirolimus-Eluting Stent or Bare Metal Stent in Acute Myocardial Infarction Study (MULTISTRATEGY) InvestigatorsJAMA20082991788179918375998
   PubMed Web of Science ®Google Scholar
• MarzocchiAManariAPiovaccariGFATA InvestigatorsRandomized comparison between tirofiban and abciximab to promote complete ST-resolution in primary angioplasty: results of the facilitated angioplasty with tirofiban or abciximab (FATA) in ST-elevation myocardial infarction trialEur Heart J2008292972298018940887
   PubMed Web of Science ®Google Scholar
• KingSBIIISmithSCHirshfeldJWJacobsAKMorrisonDAWilliamsDOFocused update of the ACC/AHA/SCAI. 2005 Guideline update for percutaneous coronary interventionJ Am Coll Cardiol20085117220918191745
   PubMed Web of Science ®Google Scholar
• SmithSCJrFeldmanTEHirshfeldJWJrACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention)J Am Coll Cardiol200647e1e12116386656
   PubMedGoogle Scholar